or Try an Advanced Search...

    Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.41 1.51% 0.02
    ATNM closed down 2.11 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ATNM trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 1.51%
    NR7 Range Contraction 1.51%
    Lower Bollinger Band Walk Weakness 1.51%
    Wide Bands Range Expansion 1.51%
    Below Lower BB Weakness 1.51%
    Lower Bollinger Band Touch Weakness 1.51%
    Oversold Stochastic Weakness 1.51%
    Jack-in-the-Box Bearish Bearish Swing Setup -0.63%
    Lower Bollinger Band Walk Weakness -0.63%
    Wide Bands Range Expansion -0.63%
    Older End-of-Day Signals for ATNM ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 3 hours ago
    Down 1% about 3 hours ago
    Up 2% about 3 hours ago
    Up 1% about 3 hours ago
    Lower Bollinger Band Support about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ATNM Chart by TradingView
    Basic chart:

    Profile

    Actinium Pharmaceuticals, Inc. Description

    Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Chemical Elements Monoclonal Antibodies Monoclonal Antibody Stem Cell Acute Myeloid Leukemia Transplantation Platform Technology Actinides Cancer Center Hematopoietic Stem Cell Iodine Bismuth Immunotherapy Technology Kettering Cancer Center Memorial Sloan

    Is ATNM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 4 Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
    Oct 18 All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
    Sep 23 Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
    Sep 20 Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
    Aug 5 Actinium: Q2 Earnings Snapshot
    Aug 5 Sector Update: Health Care Stocks Fall in Afternoon Trading
    Aug 5 Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
    Aug 5 Actinium stock tumbles 75% on FDA update for lomab-B
    Aug 5 Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
    Aug 1 Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
    See more ATNM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 10.24
    52 Week Low 1.33
    Average Volume 274,818
    200-Day Moving Average 5.48
    50-Day Moving Average 1.76
    20-Day Moving Average 1.73
    10-Day Moving Average 1.66
    Average True Range 0.13
    RSI (14) 32.43
    ADX 21.29
    +DI 12.89
    -DI 30.47
    Chandelier Exit (Long, 3 ATRs) 1.59
    Chandelier Exit (Short, 3 ATRs) 1.76
    Upper Bollinger Bands 2.06
    Lower Bollinger Band 1.39
    Percent B (%b) 0.0
    BandWidth 39.04
    MACD Line -0.10
    MACD Signal Line -0.06
    MACD Histogram -0.0441
    Fundamentals Value
    Market Cap 38.59 Million
    Num Shares 27.8 Million
    EPS -1.93
    Price-to-Earnings (P/E) Ratio -0.72
    Price-to-Sales 266.69
    Price-to-Book 3.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.51
    Resistance 3 (R3) 1.52 1.49 1.49
    Resistance 2 (R2) 1.49 1.46 1.49 1.48
    Resistance 1 (R1) 1.44 1.44 1.43 1.43 1.48
    Pivot Point 1.41 1.41 1.40 1.41 1.41
    Support 1 (S1) 1.36 1.38 1.35 1.35 1.30
    Support 2 (S2) 1.33 1.36 1.33 1.30
    Support 3 (S3) 1.28 1.33 1.29
    Support 4 (S4) 1.27